Recent research have centered on the convergence of glucagon-like peptide-1|GIP|GCGR agonist therapies and DA neurotransmission. While GLP activators are widely employed for managing type 2 T2DM, their potential effects on reward circuits, specifically influenced by dopaminergic networks, are gai